A Phase 4 interventional study of pantoprazole and pantoprazole in Peptic Ulcer Hemorrhage, sponsored by Lotung Poh-Ai Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-04-07.
Sponsored by Lotung Poh-Ai Hospital · Phase 4, Interventional, and Prevention
A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.
A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients.
In the past few years, adjuvant use of a high-dose proton pump inhibitor (PPI) after endoscopic therapy has been endorsed in some studies, two consensus statements and two meta-analysis. In our previous experience, we used omeprazole 160 mg /day infusion instead of 8 mg/h in these patients and obtained a good result .
The objectives of this study are to assess the outcomes of two different regimens of high dose of intravenous pantoprazole after endoscopic therapy in patients with peptic ulcer bleeding.
193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.
This study's enrollment of 120 is below the median of 150 across 142 interventional studies indexed under Peptic Ulcer.
Browse Peptic Ulcer studies →Lotung Poh-Ai Hospital is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
pantoprazole 40mg/q6h IV infusion for three days
Drug: pantoprazole
pantoprazole 8mg/h for three days
Drug: pantoprazole
pantoprazole 40 mg/q6h IV infusion for three days
Also known as: pantoloc
pantoprazole 8 mg/h IV infusion for three days
Also known as: pantoloc
The primary end point was recurrent bleeding before discharge and within 14 days.
Time frame: About one year
At day 14, volume of blood transfused, number of surgeries performed, and the mortality rates of the two groups are compared.
Time frame: about one year
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lotung Poh-Ai Hospital